How Covovax could help Indian students to study abroad?

The addition of the Covovax vaccine, developed by Serum Institute of India, Pune, to the list of vaccines that have been approved by the Ministry of Health, Government of India, as one of the vaccines to fight against COVID-19. The proven efficacy of the Covovax against the Omicron variant and its chances to become India’s booster shot will help Indian students who are planning to move abroad in the March intakes globally. Covovax can provide a breather to Indian students to get accepted by officials in countries across the globe.  

Get all your Study Abroad doubts clarified Now for FREE: Fix an Appointment Now

Covovax is the Indian version of the US-based Novavax vaccine. The Serum Institute of India (SSI),  also manufacturing Covishield, has been given rights to produce Covovax. The vaccine was more than 90% effective in a late-stage US-based clinical trial, as per the company. In a recent trial, it has been proved that Covovax has improved efficacy against the Omicron variant of coronavirus. In December 2021, Covovax became the 9th vaccine approved by World Health Organization (WHO)  to be included in the emergency use listing (EUL) in low-income countries.

Meanwhile, Covovax a subunit of Novavax is undergoing phase 3 trials for usage among children below the age of 18 years in India. The success of the trials will bring huge relief for the school-goers who will be elevated to the undergraduate courses. Although Drug Controller General of India (DCGI) is yet to give a nod to the usage of Covovax for children below 18 years of age, SII Chief Adar Poonawalla has hinted that the vaccine will receive approval soon.

Start Your Study Abroad Journey with upGrad Abroad